Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CD8+PD-1–ILT2+ T Cells Are an Intratumoral Cytotoxic Population Selectively Inhibited by the Immune-Checkpoint HLA-G
Clément Dumont, Alix Jacquier, Jérôme Verine, et al.
Cancer Immunology Research (2019) Vol. 7, Iss. 10, pp. 1619-1632
Open Access | Times Cited: 62

Showing 1-25 of 62 citing articles:

Deregulation of HLA-I in cancer and its central importance for immunotherapy
Ahmet Hazini, Kerry Fisher, Leonard W. Seymour
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 8, pp. e002899-e002899
Open Access | Times Cited: 137
CTLs heterogeneity and plasticity: implications for cancer immunotherapy
Shengkun Peng, Anqi Lin, Aimin Jiang, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 25
HLA-G: Too Much or Too Little? Role in Cancer and Autoimmune Disease
José Manuel Martín‐Villa, Christian Vaquero‐Yuste, Marta Molina-Alejandre, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 49
Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects
Siyuan Wang, Jiaxin Wang, Yu Xia, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 8
PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives
Zhu Zhao-yang, Yigang Jin, Jing Zhou, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 8
HLA-G Neo-Expression on Tumors
Maria Loustau, François Anna, Raphaelle Dréan, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 58
HLA-G/LILRBs: A Cancer Immunotherapy Challenge
Edgardo D. Carosella, Silvia Gregori, Diana Tronik‐Le Roux
Trends in cancer (2021) Vol. 7, Iss. 5, pp. 389-392
Open Access | Times Cited: 45
HLA-G/ILTs Targeted Solid Cancer Immunotherapy: Opportunities and Challenges
Aifen Lin, Wei‐Hua Yan
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 45
HLA-G and Other Immune Checkpoint Molecules as Targets for Novel Combined Immunotherapies
Fabio Morandi, Irma Airoldi
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 2925-2925
Open Access | Times Cited: 30
Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer
Tobias Zeller, Ira A. Münnich, Roland Windisch, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18
HLA‐G: Function, polymorphisms and pathology
Antonio Arnaiz‐Villena, Ignacio Juárez, Fabio Suárez‐Trujillo, et al.
International Journal of Immunogenetics (2020) Vol. 48, Iss. 2, pp. 172-192
Open Access | Times Cited: 49
Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Margaret L. Axelrod, Mellissa J. Nixon, Paula I. González-Ericsson, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 21, pp. 5668-5681
Open Access | Times Cited: 47
First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G
François Anna, Elodie Bôle‐Richard, Joël LeMaoult, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 3, pp. e001998-e001998
Open Access | Times Cited: 36
BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression
Ilana Mandel, Dana Haves Ziv, Ilana Goldshtein, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 9, pp. e004859-e004859
Open Access | Times Cited: 26
The Role of HLA-G in Tumor Escape: Manipulating the Phenotype and Function of Immune Cells
Lu Liu, Lijun Wang, Lihong Zhao, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 37
Prognostic Significance of Immune Checkpoints HLA-G/ILT-2/4 and PD-L1 in Colorectal Cancer
Qiong-Yuan Chen, Yuxin Chen, Qiu-Yue Han, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 30
Skin Immunity and Tolerance: Focus on Epidermal Keratinocytes Expressing HLA-G
Guillaume Mestrallet, Nathalie Rouas‐Freiss, Joël LeMaoult, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 28
The Molecular Mechanisms of HLA-G Regulatory Function on Immune Cells during Early Pregnancy
Jia Mao, Ying Feng, Xiaofeng Zhu, et al.
Biomolecules (2023) Vol. 13, Iss. 8, pp. 1213-1213
Open Access | Times Cited: 12
Prognostic value of human leukocyte antigen G expression in solid tumors: a systematic review and meta-analysis
Jorge Bartolomé, Consolación Molto, Javier David Benítez Fuentes, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Soluble HLA-G and HLA-G Bearing Extracellular Vesicles Affect ILT-2 Positive and ILT-2 Negative CD8 T Cells Complementary
Esther Schwich, Gia‐Gia T. Hò, Joël LeMaoult, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 31
The Role of HLA-G in Human Papillomavirus Infections and Cervical Carcinogenesis
Huihui Xu, Wei‐Hua Yan, Aifen Lin
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 28
The Human Leukocyte Antigen G as an Immune Escape Mechanism and Novel Therapeutic Target in Urological Tumors
Simon Jasinski-Bergner, Markus Eckstein, Helge Taubert, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 18
A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes
Huihui Xu, Huili Wang, Tong-Jin Xing, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 16
Chronic lung allograft dysfunction is associated with an early increase of circulating cytotoxic CD4+CD57+ILT2+ T cells, selectively inhibited by the immune check-point HLA-G
Olivier Brugière, Domitille Mouren, Julie Trichereau, et al.
The Journal of Heart and Lung Transplantation (2022) Vol. 41, Iss. 5, pp. 626-640
Open Access | Times Cited: 14
The HLA-G immune checkpoint: a new immuno-stimulatory role for the α1-domain-deleted isoform
Diana Tronik‐Le Roux, Marina Daouya, Alix Jacquier, et al.
Cellular and Molecular Life Sciences (2022) Vol. 79, Iss. 6
Closed Access | Times Cited: 13
Page 1 - Next Page

Scroll to top